Log In
BCIQ
Print this Print this
 

lorlatinib (PF-06463922)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionInhibitor of anaplastic lymphoma kinase (ALK) and c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)
Molecular Target Anaplastic lymphoma kinase (ALK) ; c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1)
Mechanism of ActionAnaplastic lymphoma kinase (ALK) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat ALK-positive advanced non-small cell lung cancer (NSCLC); Treat ROS1-positive advanced non small cell lung cancer (NSCLC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today